The effect of two methods of transcutaneous supraorbital nerve stimulation and transcutaneous infraorbital nerve stimulation in improving clinical symptoms in patients with migraine

A comparative study of the effect of two methods of transcutaneous supraorbital nerve stimulation and transcutaneous infraorbital nerve stimulation in improving clinical symptoms and preventing a new attack in patients with migraine

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N37

Enrollment

Registered

2021-08-14

Start date

2021-08-22

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine, unspecified, not intractable, without status migrainosus

Interventions

Intervention 1: Intervention group: Intervention group 1: For patients, TENS therapy is performed through the electrode pads for the TENS device in the bilateral supraorbital area (intensity: 10 mA, w

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age category above 18 and under 65 years Patients with migraine

Exclusion criteria

Exclusion criteria: Use of migraine prevention in the last two weeks Use of migraine prevention methods such as nerve block, Botox injection, etc. in the previous year Headache due to overdose medication Having severe psychiatric illnesses or physical disorders Having other types of headaches (such as tension and clustering) Pregnancy and lactation Opioid use Failure to complete treatment sessions

Design outcomes

Primary

Measure	Time frame
Migraine severity. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Questionnare of Headache Impact Test 6 score (HIT-6).;Disability score in a person's life. Timepoint: Before the intervention, 1 and 3 months after the intervention. Method of measurement: Migrain disability assessment test (MIDAS).;Pain. Timepoint: Before the intervention, 1 and 3 months after the intervention. Method of measurement: Visual Analog Scale (VAS).	—

Measure

Time frame

Migraine severity. Timepoint: Before the intervention and three months after the intervention. Method of measurement: Questionnare of Headache Impact Test 6 score (HIT-6).;Disability score in a person's life. Timepoint: Before the intervention, 1 and 3 months after the intervention. Method of measurement: Migrain disability assessment test (MIDAS).;Pain. Timepoint: Before the intervention, 1 and 3 months after the intervention. Method of measurement: Visual Analog Scale (VAS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeid Khosrawi

Esfahan University of Medical Sciences

khosrawi@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026